Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children

A prospective multicenter study

Maria Luisa Bianchi, Rolando Cimaz, Maria Bardare, Francesco Zulian, Loredana Lepore, Antonella Boncompagni, Elena Galbiati, Fabrizia Corona, Giovanni Luisetto, Diego Giuntini, Paolo Picco, Maria Luisa Brandi, Fernanda Falcini

Research output: Contribution to journalArticle

186 Citations (Scopus)

Abstract

Objective. Osteopenia/osteoporosis is being increasingly reported as a complication of many chronic diseases, even in children. In this preliminary study, we evaluated the effect of an oral bisphosphonate (alendronate) on bone mass in children with diffuse connective tissue diseases. Methods. Thirty-eight children with low bone mass were treated with alendronate for 1 year; 38 children who had the same primary disorders as the study patients but in a less severe form served as untreated control patients. We were also able to evaluate changes in bone mass (before and after alendronate) in 16 of the treated patients whose bone mineral density (BMD) had been routinely measured before the present study was initiated. Results. BMD increased by a mean ± SD of 14.9 ± 9.8% (P <0.002 versus baseline) in the treated patients (reaching the normal range in 13 patients), while the BMD was 2.6 ± 5% (not significant versus baseline) in the control group (15 had a decrease). Most interestingly, there was a large increase in BMD (15.3 ± 9.9%) after alendronate therapy in the 16 children who had their BMD followed up in the year before the study, during which time they had shown little increase in BMD (1.03 ± 6.3%), and often a decrease. Considering their condition, increases in the height of all patients was satisfactory. No new fractures were observed after alendronate therapy was initiated. Conclusion. Bisphosphonates can be considered essential components of the treatment of secondary osteoporosis, not only in adults, but also in pediatric patients. Alendronate has a positive effect on secondary osteopenia/osteoporosis in children with connective tissue diseases.

Original languageEnglish
Pages (from-to)1960-1966
Number of pages7
JournalArthritis and Rheumatism
Volume43
Issue number9
DOIs
Publication statusPublished - 2000

Fingerprint

Alendronate
Connective Tissue Diseases
Osteoporosis
Multicenter Studies
Bone Density
Prospective Studies
Safety
Metabolic Bone Diseases
Diphosphonates
Bone and Bones
Therapeutics
Reference Values
Chronic Disease
Pediatrics
Control Groups

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children : A prospective multicenter study. / Bianchi, Maria Luisa; Cimaz, Rolando; Bardare, Maria; Zulian, Francesco; Lepore, Loredana; Boncompagni, Antonella; Galbiati, Elena; Corona, Fabrizia; Luisetto, Giovanni; Giuntini, Diego; Picco, Paolo; Brandi, Maria Luisa; Falcini, Fernanda.

In: Arthritis and Rheumatism, Vol. 43, No. 9, 2000, p. 1960-1966.

Research output: Contribution to journalArticle

Bianchi, Maria Luisa ; Cimaz, Rolando ; Bardare, Maria ; Zulian, Francesco ; Lepore, Loredana ; Boncompagni, Antonella ; Galbiati, Elena ; Corona, Fabrizia ; Luisetto, Giovanni ; Giuntini, Diego ; Picco, Paolo ; Brandi, Maria Luisa ; Falcini, Fernanda. / Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children : A prospective multicenter study. In: Arthritis and Rheumatism. 2000 ; Vol. 43, No. 9. pp. 1960-1966.
@article{6d5a89b1e47f465aaab3e242b7c60a98,
title = "Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: A prospective multicenter study",
abstract = "Objective. Osteopenia/osteoporosis is being increasingly reported as a complication of many chronic diseases, even in children. In this preliminary study, we evaluated the effect of an oral bisphosphonate (alendronate) on bone mass in children with diffuse connective tissue diseases. Methods. Thirty-eight children with low bone mass were treated with alendronate for 1 year; 38 children who had the same primary disorders as the study patients but in a less severe form served as untreated control patients. We were also able to evaluate changes in bone mass (before and after alendronate) in 16 of the treated patients whose bone mineral density (BMD) had been routinely measured before the present study was initiated. Results. BMD increased by a mean ± SD of 14.9 ± 9.8{\%} (P <0.002 versus baseline) in the treated patients (reaching the normal range in 13 patients), while the BMD was 2.6 ± 5{\%} (not significant versus baseline) in the control group (15 had a decrease). Most interestingly, there was a large increase in BMD (15.3 ± 9.9{\%}) after alendronate therapy in the 16 children who had their BMD followed up in the year before the study, during which time they had shown little increase in BMD (1.03 ± 6.3{\%}), and often a decrease. Considering their condition, increases in the height of all patients was satisfactory. No new fractures were observed after alendronate therapy was initiated. Conclusion. Bisphosphonates can be considered essential components of the treatment of secondary osteoporosis, not only in adults, but also in pediatric patients. Alendronate has a positive effect on secondary osteopenia/osteoporosis in children with connective tissue diseases.",
author = "Bianchi, {Maria Luisa} and Rolando Cimaz and Maria Bardare and Francesco Zulian and Loredana Lepore and Antonella Boncompagni and Elena Galbiati and Fabrizia Corona and Giovanni Luisetto and Diego Giuntini and Paolo Picco and Brandi, {Maria Luisa} and Fernanda Falcini",
year = "2000",
doi = "10.1002/1529-0131(200009)43:9<1960::AID-ANR6>3.0.CO;2-J",
language = "English",
volume = "43",
pages = "1960--1966",
journal = "Arthritis care and research : the official journal of the Arthritis Health Professions Association",
issn = "0893-7524",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children

T2 - A prospective multicenter study

AU - Bianchi, Maria Luisa

AU - Cimaz, Rolando

AU - Bardare, Maria

AU - Zulian, Francesco

AU - Lepore, Loredana

AU - Boncompagni, Antonella

AU - Galbiati, Elena

AU - Corona, Fabrizia

AU - Luisetto, Giovanni

AU - Giuntini, Diego

AU - Picco, Paolo

AU - Brandi, Maria Luisa

AU - Falcini, Fernanda

PY - 2000

Y1 - 2000

N2 - Objective. Osteopenia/osteoporosis is being increasingly reported as a complication of many chronic diseases, even in children. In this preliminary study, we evaluated the effect of an oral bisphosphonate (alendronate) on bone mass in children with diffuse connective tissue diseases. Methods. Thirty-eight children with low bone mass were treated with alendronate for 1 year; 38 children who had the same primary disorders as the study patients but in a less severe form served as untreated control patients. We were also able to evaluate changes in bone mass (before and after alendronate) in 16 of the treated patients whose bone mineral density (BMD) had been routinely measured before the present study was initiated. Results. BMD increased by a mean ± SD of 14.9 ± 9.8% (P <0.002 versus baseline) in the treated patients (reaching the normal range in 13 patients), while the BMD was 2.6 ± 5% (not significant versus baseline) in the control group (15 had a decrease). Most interestingly, there was a large increase in BMD (15.3 ± 9.9%) after alendronate therapy in the 16 children who had their BMD followed up in the year before the study, during which time they had shown little increase in BMD (1.03 ± 6.3%), and often a decrease. Considering their condition, increases in the height of all patients was satisfactory. No new fractures were observed after alendronate therapy was initiated. Conclusion. Bisphosphonates can be considered essential components of the treatment of secondary osteoporosis, not only in adults, but also in pediatric patients. Alendronate has a positive effect on secondary osteopenia/osteoporosis in children with connective tissue diseases.

AB - Objective. Osteopenia/osteoporosis is being increasingly reported as a complication of many chronic diseases, even in children. In this preliminary study, we evaluated the effect of an oral bisphosphonate (alendronate) on bone mass in children with diffuse connective tissue diseases. Methods. Thirty-eight children with low bone mass were treated with alendronate for 1 year; 38 children who had the same primary disorders as the study patients but in a less severe form served as untreated control patients. We were also able to evaluate changes in bone mass (before and after alendronate) in 16 of the treated patients whose bone mineral density (BMD) had been routinely measured before the present study was initiated. Results. BMD increased by a mean ± SD of 14.9 ± 9.8% (P <0.002 versus baseline) in the treated patients (reaching the normal range in 13 patients), while the BMD was 2.6 ± 5% (not significant versus baseline) in the control group (15 had a decrease). Most interestingly, there was a large increase in BMD (15.3 ± 9.9%) after alendronate therapy in the 16 children who had their BMD followed up in the year before the study, during which time they had shown little increase in BMD (1.03 ± 6.3%), and often a decrease. Considering their condition, increases in the height of all patients was satisfactory. No new fractures were observed after alendronate therapy was initiated. Conclusion. Bisphosphonates can be considered essential components of the treatment of secondary osteoporosis, not only in adults, but also in pediatric patients. Alendronate has a positive effect on secondary osteopenia/osteoporosis in children with connective tissue diseases.

UR - http://www.scopus.com/inward/record.url?scp=0033679539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033679539&partnerID=8YFLogxK

U2 - 10.1002/1529-0131(200009)43:9<1960::AID-ANR6>3.0.CO;2-J

DO - 10.1002/1529-0131(200009)43:9<1960::AID-ANR6>3.0.CO;2-J

M3 - Article

VL - 43

SP - 1960

EP - 1966

JO - Arthritis care and research : the official journal of the Arthritis Health Professions Association

JF - Arthritis care and research : the official journal of the Arthritis Health Professions Association

SN - 0893-7524

IS - 9

ER -